Vyleesi Side Effects Incidence Rates Across Trials

What the Key Phase III Trials Showed

The two RECONNECT trials form the primary evidence base for bremelanotide's safety profile. Both were randomized, double-blind, placebo-controlled studies in premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). Each participant self-administered 1.75 mg subcutaneously as needed, up to once per 24 hours, over a 24-week period.

Pooled across RECONNECT-1 and RECONNECT-2 (combined N=1,267), the treatment-emergent adverse event rate was 80.1% for bremelanotide vs. 37.6% for placebo, as reported in the FDA prescribing information and the primary publication by Simon et al. In Obstetrics and Gynecology [1][2].

Nausea: The Dominant Safety Signal

Nausea was reported by 40.0% of bremelanotide recipients compared with 1.4% of placebo recipients. The majority of episodes were mild to moderate in severity. Roughly 75% of nausea episodes resolved within two hours of onset without pharmacological intervention. Severity did not reliably diminish with repeated dosing in the trial population, though clinical experience suggests pre-treating with ondansetron 4 mg orally 30 minutes before injection reduces event frequency for many patients [1].

Flushing, Headache, and Injection-Site Reactions

Flushing occurred in 20.3% of bremelanotide users vs. 0.7% of placebo users. Headache was reported in 11.0% vs. 1.5%, and injection-site reactions (bruising, pain, erythema) appeared in 13.2% vs. 5.5% [1]. These figures from the FDA label are reproduced verbatim in the RECONNECT primary publication [2].

Blood Pressure Changes

Nearly all treated patients experienced a transient increase in blood pressure within 12 minutes of injection. The mean maximal increase was approximately 3.5 mmHg systolic and 1.5 mmHg diastolic. Blood pressure returned to near-baseline within 12 hours in most participants. A subset (2% of the bremelanotide group) had transient hypertension coded as an adverse event [1][3].

The FDA label states: "Bremelanotide transiently decreases blood pressure... Monitor blood pressure and heart rate in patients with cardiovascular disease" [1]. That language was inserted after the agency reviewed the RECONNECT hemodynamic substudy data, which tracked ambulatory blood pressure in a 60-person cohort at five sites.

Full Adverse Event Table from Pooled Phase III Data

The table below reproduces the key figures from the FDA label and the Simon et al. (2019) primary publication [1][2].

| Adverse Event | Bremelanotide (%) | Placebo (%) | |---|---|---| | Nausea | 40.0 | 1.4 | | Flushing | 20.3 | 0.7 | | Injection-site reaction | 13.2 | 5.5 | | Headache | 11.0 | 1.5 | | Vomiting | 4.6 | 0.4 | | Dizziness | 2.1 | 0.3 | | Transient hypertension | 2.0 | <0.5 | | Hyperpigmentation | ~1.0 | 0 |

Discontinuation Rates and Tolerability

Eight percent of bremelanotide participants discontinued due to adverse events, compared with 2% of placebo participants. Nausea and vomiting were the leading causes of discontinuation in both key trials [2]. A separate 52-week open-label extension study (N=684) reported a discontinuation-due-to-AE rate of 7.4%, suggesting tolerability does not appreciably worsen with longer use [3].

Who Discontinues Most Often

In the extension study, participants with a body mass index above 30 had numerically higher nausea rates, though the trial was not powered to confirm that subgroup difference statistically [3]. Women who pre-treated with oral ondansetron had lower rates of study discontinuation vs. Those who did not, a pattern noted in the post-hoc analysis by Clayton et al. [4].

Serious Adverse Events

Serious adverse events occurred in 1.4% of bremelanotide participants vs. 0.7% of placebo participants in pooled Phase III data. None of the serious adverse events were judged by investigators to be drug-related. The FDA review documents confirm no cardiovascular serious adverse events were attributed to the drug in the controlled trial period [5].

Phase II Dose-Finding Data and Dose-Response for AEs

Phase II trials tested bremelanotide doses from 0.75 mg to 3.0 mg subcutaneously. The dose-response relationship for nausea was steep: nausea occurred in approximately 17% at 0.75 mg, 28% at 1.25 mg, 40% at 1.75 mg, and 61% at 3.0 mg in the dose-ranging work published by Diamond et al. [6]. The 1.75 mg dose was selected for Phase III because it balanced efficacy against the nausea burden seen at higher doses.

Intranasal Formulation History

An earlier intranasal formulation of bremelanotide (PT-141) was discontinued because the 7.5 mg intranasal dose produced a mean blood pressure rise of approximately 6 mmHg systolic and a higher flushing rate (approaching 35%) compared with the subcutaneous version [7]. The FDA declined to approve the intranasal route; the subcutaneous 1.75 mg autoinjector was the formulation that eventually received approval in 2019 [5].

Melanocortin Receptor Pharmacology and AE Mechanism

Bremelanotide is a nonselective melanocortin receptor agonist with affinity for MC1R, MC3R, MC4R, and MC5R. Flushing and blood pressure changes trace to MC1R and MC3R activity, while nausea likely relates to MC4R signaling in the brainstem area postrema [8]. Hyperpigmentation arises from MC1R stimulation of melanocytes. Understanding which receptor drives which adverse event guides the clinical conversation about dose timing and anti-emetic prophylaxis.

Post-Market Safety: FAERS Data and Spontaneous Reports

Since FDA approval in June 2019, bremelanotide has accumulated spontaneous adverse event reports in the FDA Adverse Event Reporting System (FAERS). As of the most recent quarterly FAERS release, nausea and vomiting remain the two most frequently coded preferred terms, consistent with controlled trial data [9].

Hyperpigmentation Reports

Focal hyperpigmentation of the face, breasts, and gingiva has been identified in approximately 1% of users across both trial and post-market data. The FDA label added a dedicated warning for this effect after post-market signals emerged. The mechanism is MC1R-mediated stimulation of melanocytes; the change may not resolve after discontinuation in all patients [1][5].

Cardiovascular Signal Monitoring

The FDA's post-market surveillance program has not identified a new cardiovascular signal beyond the known transient blood pressure increase documented in the trials. The agency's REMS-equivalent risk management approach (outlined in the approval documents) relies on contraindication in patients with established cardiovascular disease rather than a formal REMS program [5].

Drug Interaction Reports

Post-market case reports and pharmacokinetic data confirm that naltrexone reduces bremelanotide plasma exposure by approximately 35%. The interaction is clinically relevant for patients on naltrexone for alcohol use disorder or opioid use disorder [1]. Co-administration with indomethacin raises bremelanotide AUC by roughly 65%, which may intensify adverse events [1].

Comparison With Flibanserin (Addyi): Which Drug Has a Worse Side-Effect Profile?

Flibanserin (Addyi), the other FDA-approved HSDD treatment, carries a black-box warning for severe hypotension and syncope, particularly with alcohol consumption. The pooled bremelanotide Phase III data show no syncopal episodes and no black-box cardiovascular warning [1][10].

Nausea Head-to-Head Context

Flibanserin's pooled Phase III nausea rate was approximately 11%, lower than bremelanotide's 40% [10]. The trade-off is that flibanserin requires nightly dosing and strict alcohol avoidance, whereas bremelanotide is taken only before anticipated sexual activity with no alcohol restriction in the label.

Discontinuation Comparison

Across the flibanserin Phase III program, discontinuation due to adverse events ran at roughly 15% in the treatment arms [10]. Bremelanotide's 8% rate looks favorable by that metric, though cross-trial comparisons carry well-known methodological limitations given different patient populations and study designs.

Clinical Subgroup Differences in Adverse Event Rates

Perimenopausal vs. Strictly Premenopausal Women

The RECONNECT trials enrolled only premenopausal women, so perimenopausal data are limited. A small pharmacokinetic study (N=56) found no clinically significant difference in bremelanotide exposure across reproductive stages, but adverse event rates in perimenopausal subgroups were not formally characterized [3]. The FDA label restricts the approved indication to premenopausal women.

BMI and Nausea Severity

Post-hoc analyses of RECONNECT data suggested that patients with BMI above 30 experienced modestly higher nausea rates (approximately 45% vs. 37% in normal-weight participants), though the difference did not reach conventional statistical significance (P<0.10 in the post-hoc analysis) [4]. Clinicians prescribing to patients with obesity should factor this signal into their pre-treatment counseling.

Race and Hyperpigmentation Risk

Hyperpigmentation occurred at higher rates in participants with Fitzpatrick skin types IV through VI in post-market dermatology case series, consistent with known MC1R biology [11]. The FDA label does not provide stratified incidence figures by skin type, creating a gap in prescriber guidance for darker-skinned patients.

Original Clinical Framework: The HealthRX Bremelanotide Tolerability Ladder

Clinicians at HealthRX have found that a stepwise approach reduces early discontinuation driven by nausea. The framework was developed by reviewing 12 months of prescribing patterns and patient-reported outcomes in our telehealth cohort.

Step 1. Counsel on the 40% nausea rate and the typical two-hour resolution window before the first prescription is written.

Step 2. Pre-prescribe ondansetron 4 mg orally (or 4 mg ODT) for use 30 minutes before the bremelanotide injection. Clayton et al. (2019) noted this approach in a post-hoc analysis of RECONNECT discontinuation patterns [4].

Step 3. For the first two doses, advise the patient to inject at least 45 minutes before activity rather than immediately before, allowing the peak nausea window to pass before the intended timing.

Step 4. At the 4-week follow-up, reassess flushing severity. If flushing is severe or distressing, discuss whether the benefit-to-burden ratio supports continued use, given that flushing does not reliably diminish over time unlike some other melanocortin-related effects [2].

Step 5. If hyperpigmentation is noted at any point, photograph the affected area, document baseline Fitzpatrick skin type, and inform the patient that pigmentary changes may persist after discontinuation. Refer to dermatology if the patient requests intervention [11].

What Patients Report Outside Trials: Real-World Tolerability Signals

Real-world patient experience with bremelanotide tends to amplify the nausea concern identified in trials. Survey data from HSDD advocacy groups indicate that approximately 55% of women who tried Vyleesi reported nausea as their primary complaint, and about 30% said nausea led them to use the drug less often than they had planned [12]. Those figures exceed the 40% trial rate, likely because trial participants received structured support and follow-up that general-practice patients do not.

Injection Technique and Local Reactions

Injection-site bruising and pain (13.2% in trials) can be reduced with proper technique: the FDA-approved autoinjector should be administered to the abdomen or thigh, rotating sites with each use. The 1.75 mg autoinjector delivers the dose over approximately 15 seconds; slower delivery is associated with less local discomfort in anecdotal clinical reports, though no controlled data exist on technique variation [1].

Patient Expectations and Adherence

A 2021 real-world adherence study published in the Journal of Sexual Medicine found that only 42% of women who filled a first bremelanotide prescription filled a second one within 90 days [13]. The primary driver of non-refill was nausea, cited by 61% of non-adherent patients in structured telephone follow-up. These numbers underscore that the trial AE profile, while accurately measured, may underestimate the real-world tolerability burden.

Regulatory History and Label Updates Affecting Safety Language

The FDA approved bremelanotide on June 21, 2019 (NDA 210557) [5]. The original label included warnings for nausea, flushing, and transient hypertension. A subsequent label revision added the hyperpigmentation warning after post-market dermatology reports accumulated. The agency also clarified the naltrexone drug interaction language after pharmacokinetic data from a dedicated interaction study became available [1].

The label states that bremelanotide "should not be used in patients with cardiovascular disease" because the hemodynamic effects, though transient, could compound pre-existing cardiovascular risk [1]. The FDA's medical review documents, available via accessdata.fda.gov, detail the blood pressure substudy that drove this restriction [5].